PRESS RELEASE

AAA strengthens European radiopharmaceutical manufacturing network
Acquires two well established companies in Spain

January 29, 2013 (Saint Genis Pouilly, France): Advanced Accelerator Applications (“AAA”), the fast-growing international Molecular Nuclear Medicine (“MNM”) company, announced today that it has acquired two radiopharmaceutical companies in Barcelona, Spain: Barnatron and Catalana De Dispensación, S.A. (Cadisa) from ERESA Grupo Medico (majority shareholder) and Molypharma.

Barnatron
Established in 2001, Barnatron is an authorised manufacturer and distributor of radiopharmaceuticals for diagnostic use in Positron Emission Tomography (PET). The company’s manufacturing laboratory is the only one in Spain to have two high-capacity cyclotrons, which ensure reliable delivery to its customers in Catalonia, Madrid, Andalucia, the Balearics, Levante, La Rioja, Aragón and the Canary Islands. Barnatron also works closely with the Experimental Molecular Imaging Centre (CIME), conducting research into new radiopharmaceuticals in collaboration with the Unit of Glycocojugate Chemistry from the Spanish National Research Council (CSIC). For the year ended 2012, Barnatron had sales totaling €2.6 million.

Cadisa
Cadisa was established in 1995. The company manufactures and supplies radiopharmaceutical products for Single Photon Emission Tomography (SPECT) to hospitals in Spain. Its facility is approved by the Nuclear Safety Council and the Ministry of Health and has the capacity to produce more than 100,000 doses per year. For the year ended 2012, the company had sales totaling €2.6 million.

ERESA Grupo Medico is a medical diagnostics service provider, operating in over 40 centres around Spain. AAA has signed a long-term agreement with ERESA to supply PET and SPECT products to all of ERESA centres, existing and new, across Spain.

These acquisitions further strengthen AAA’s leading position in peninsula Ibérica. With its current facilities in Zaragoza and Porto, and one under construction in Murcia, the Company will be able to efficiently supply the entire market.

Isabela Ramírez de Arellano, Barnatron and Cadisa’s General Manager commented: “We are excited by the opportunity to be part of AAA. Both companies are committed to developing new and research PET tracers for the Spanish MNM market. AAA’s global expertise and customer-oriented approach will be increasingly valuable as we continue to expand the business.”

Stefano Buono, Chief Executive Officer of AAA, added: “The acquisitions of Cadisa and Barnatron follow our recent entry into the Polish market and are another step forward in our strategy to aggressively expand our European PET manufacturing network.

AAA operates 10 European laboratories serving eight countries and has several others under construction. With the increasing demand for better diagnosis leading to cost-effective treatment, the MNM market is experiencing significant growth. There are currently 20 new proprietary F-18 products in clinical development; the first was approved two weeks ago by the EMA for
Alzheimer's disease. We believe many of the others will reach the market in the next four to five years and will need to be produced in Europe. PET tracers are very challenging to manufacture due to their short shelf life of approximately 10 hours. With our specialised European expertise and extensive growing network of laboratories, we believe we are well-placed to profitably manufacture these molecules for both existing and new partners.”

Marta Saus Cano, CEO of ERESA Grupo Medico commented: “Cadisa and Barnatron are strong, profitable businesses with significant growth potential. However as a medical diagnostics service provider, MNM is outside our core area of expertise. AAA is a leader in this market and we believe it is the right company to take these businesses to the next stage of growth.”

Contacts

**Advanced Accelerator Applications SA**
Véronique Mermet
20 rue Diesel
01630 Saint Genis Pouilly, France
www.adacap.com
info@adacap.com
Tel: +33 4 50 99 30 70

**ERESA Grupo Médico (Spain)**
Iñaki Lucas Pérez
C/ Marqués de San Juan, 6
46015 Valencia, Spain
www.eresa.com
Email: ilucas@eresa.com
Tel: +34 963 404 077

Media enquiries

**FTI Consulting (UK)**
Stephanie Cuthbert
Email: Stephanie.Cuthbert@fticonsulting.com
Tel: +44 (0)20 3077 0458
Julia Phillips
Email: Julia.phillips@fticonsulting.com
Tel: +44 (0)20 7269 7187

**Twister Communications Group (Italy)**
Annalisa Bassi
Email: abassi@twistergroup.it
Tel: +39 02 438114218
Elisa Piacentino
Email: epiacentino@twistergroup.it
Tel: +39 02 438114602

About Advanced Accelerator Applications

Advanced Accelerator Applications (www.adacap.com), is a European pharmaceutical company founded in 2002 to develop innovative diagnostic and therapeutic products. AAA’s main focus is in the field of Molecular Imaging and targeted, individualised therapy for the management of patients with serious conditions (Personalized Medicine). AAA currently has 16 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products and more than 240 employees in 10 countries (France, Italy, Germany, Switzerland, Spain, Poland, Portugal, Israel, U.S., Canada).

In 2011 AAA reported revenues of €35.8 million (+20.6% vs. 2010), an EBITDA of €5.94 million and R&D investment and charges in excess of €13 million (39% of sales).
EREASA

GRUPO ERESA (Exploraciones Radiológicas Especiales S.A.) is a business group which provides specialized medical services with the latest technology.

With four decades of professional experience in its field, today Grupo ERESA is the leading company in Comprehensive Diagnostic, integrating Radiology, Nuclear Medicine Diagnostic and Genetic Diagnostic, as well as Radiation Oncology.

Besides taking a very positive view on the quality of ERESA’s services, its clients also value the professional attitude of the team. Great background experience gained over many years allows us to provide for each client a solution that fits his/her exact needs.

ERESA Grupo Medico has internalized its diagnostic imaging, radiation oncology and Nuclear medicine services in a total of 11 hospitals in the health network in the Valencian Community, after successive Awards obtained in public tenders. ERESA also provides its services to hospitals in Extremadura, Madrid, the Canary Islands and Catalonia, whether public or private, adapting its services to the needs of the hospitals.

About Molecular Nuclear Medicine

Molecular Nuclear Medicine is a medical specialty using trace amounts of active substances, called radiopharmaceuticals, to create images of organs and lesions and to treat various diseases, like cancer. The technique works by injecting into the patient's body targeted radiopharmaceuticals that accumulate in the organs or lesions that reveal specific biochemical processes.

Molecular Nuclear Diagnostics employs a variety of imaging devices and radiopharmaceuticals. PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) are highly sensitive imaging technologies that enable physicians to diagnose different types of cancer, cardiovascular diseases, neurological disorders and other diseases in their early stages.

PET (Positron Emission Tomography) is a MNM imaging technique used in diagnosis and biomedical research. In PET, a chemical compound labeled with a short-lived positron-emitting radionuclide of Rubidium, Gallium, Carbon, Oxygen, Nitrogen, or Fluorine is injected into the body. The activity of such a radiopharmaceutical is quantitatively measured throughout the target organs. Data are analyzed and reconstructed by means of a computer to produce images of the organs being scanned.

SPECT (Single Photon Emission Computed Tomography) is a MNM imaging technique similar to PET but that uses gamma emitting radionuclides such as Technetium, Iodine or Indium.